Changing the fundamental way in which cellular analysis is conducted, LevitasBio is striving for a healthier future. Indeed, utilising innovative magnetic levitation technology, the company has created a fast, efficient, and simple way to conduct studies in this arena. As such, it has been awarded the title, Leading Innovators in Cellular Analysis 2022 – USA.
LevitasBio is the company behind innovative products that have the potential to change the way cellular analysis is conducted around the globe. Indeed, after years of stagnation in the sample preparation and cellular analysis market, LevitasBio is providing the first truly unique approach to cellular analysis in three decades. Supported by a leadership team that possesses over 150 years of combined experience and a scientific founding team filled with experts, the company has utilised a combination of science and creativity in order to better the industry, resulting in the effective LeviCell™ 1.0, LeviPrep™, LeviSelect™, and LeviCell™ EOS systems.
In a press release issued by the company’s website, Martin Piepryzk, CEO of LevitasBio, says, ‘our aim is to empower our customers to discover what is currently hidden in their samples,’ he continues, ‘by enabling researchers to gain access to specifically enriched viable cells from difficult starting samples while simultaneously characterizing the sample, we are opening the door to previously inaccessible discoveries.’ This ties into the company’s mission – to advance human health by providing researchers with a better and more powerful way to conduct cellular analysis.
Traditional methods used to separate specific cell types from a mixed population include magnetic beads, gradient purification, and flow cytometry. However, the inherent issue with these techniques is that they are not the most efficient ways to enrich a target cell population – whilst they may be widely used, there is great room for improvement. For example, magnetic beads require around 34 minutes of hands-on time, 11 pipette steps, and a total time of approximately 69 minutes.
LevitasBio’s LeviCellTM EOS platform is capable of separating cells in 80% less time than commonly used methods, such as fluorescence-activated cell sorting (FACS.) Necessitating only two minutes of hands-on time, the product uses an autopilot system, which enables the process to be complete in as soon as 21 minutes. Serving as the next generation of sample processing technology, the LeviCellTM EOS offers a higher throughput, scalability, and ultimate flexibility. The accompanying software allows for centralised control, possessing an optimised dashboard, the software facilitates quick file download of run logs, management of all connect modules, and offers access to powerfully intuitive instructions.
Additionally, the LeviPrepTM range acts as the fundamental step of an integrated workflow for challenging primary tissue work. The kitted reagent, combined with the power of Levitation Technology and the LeviCellTM EOS system, acts as a catalyst for the streamlining of experiments. Furthermore, it acts as a way to make the enrichment of highly viable cells with minimal perturbations and free of debris, dead or dying cells more accessible. The flagship product in this range, the LeviPrep Mouse Tissue Dissociation Kit, can dissociate brain, liver and lung organs using a fast and easy pre-optimised cold dissociation protocol.
Behind such devices is technology created at the prestigious Stanford University, a private research university in Stanford, California. Extensive research has shown that cells of different types or states have unique physical signatures, levitating in predictable ways when they encounter a magnetic density field. Within LevitasBio’s LiviCellTM products, this takes place across a five-step process – sample introduction, magnetic levitation, stabilisation & measuring, cell separation, and collection.
Of course, the company’s devotion to advancing science is unsurprising – the leadership team is comprised of veterans within the life science and diagnostic markets. Graduates of leading universities, including UC Berkley and Santa Clara University, the leadership team boasts an abundance of accomplishments. This includes 50 issued patents and inventions, including single cell genomics and the first technology that commercialised microfluidics. Moreover, the company’s vibrant scientific founding team are all current faculty members at Stanford University and are some of the brightest stars within the biotech field.
Consequently, LevitasBio has cultivated a stable structure within which its team can thrive. Communication, transparency, and creativity are all greatly valued traits within both leadership roles and positions within the wider team. It is expected that the staff members apply themselves to the job at hand, pushing themselves to learn and grow – not only as professionals, but also as people. Henceforth, LevitasBio has a high staff retention rate and a devoted workforce.
This is a great benefit as the company explores its future options. In the meantime, the company has numerous appearances planned throughout 2022. LevitasBio will be showcasing its expertise at conferences around the world, including the IACR (Irish Association for Cancer Research) conference in Cork, Ireland, PMWC’s Innovation Showcase, and the EACR (European Association for Cancer Research) conference in Seville, Spain.
For business enquiries, contact Lawreen Asuncion from LevitasBio ontheir website – https://levitasbio.com/